Physician profile
Abdallah Osman
NPI 1164003034
$698.30
in general payments reported to CMS, 2019-2025
14 companies · $545 in 2025
The $545 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $153 · 2025: $545.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.41 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $277.36 | 2024-2025 | |
| Novo Nordisk INC | $68.28 | 2024-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $53.02 | 2024-2025 | Rexulti |
| Amgen INC. | $41.92 | 2024-2025 | Evenity, Prolia, Prolia |
| Sumitomo Pharma America, INC. | $40.52 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $36.53 | 2024 | |
| Abiomed | $34.18 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.23 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.33 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $23.37 | 2024 | Xarelto |
| Insulet Corporation | $20.38 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.03 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $15.46 | 2025 | Arexvy |
| Aimmune Therapeutics, INC. | $14.69 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdallah Osman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.